Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019. We show 42 historical shares outstanding datapoints in our TBPH shares outstanding history coverage, used to compute TBPH market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TBPH market cap history over the course of time is important for investors
interested in comparing TBPH's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TBPH versus a peer is one thing; comparing
TBPH market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TBPH can fluctuate over the course of history.
With this page we aim to empower investors researching TBPH by allowing them to research the TBPH market cap history. |
Free TBPH Email Alerts:
Video: The Importance of Market Cap
